Cargando…
Survival After Treatable Hepatocellular Carcinoma Recurrence in Liver Recipients: A Nationwide Cohort Analysis
BACKGROUND: Survival after post-transplant recurrence of HCC is dismal, and almost all treatments for recurrent HCC are off-labeled, without an extensive large-scale analysis. We aimed to delineate their post-recurrence courses and define benchmarks for comparing future treatment effectiveness. METH...
Autores principales: | Ho, Cheng-Maw, Lee, Chih-Hsin, Lee, Ming-Chia, Zhang, Jun-Fu, Chen, Chin-Hua, Wang, Jann-Yuan, Hu, Rey-Heng, Lee, Po-Huang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7883828/ https://www.ncbi.nlm.nih.gov/pubmed/33598433 http://dx.doi.org/10.3389/fonc.2020.616094 |
Ejemplares similares
-
Nationwide Longitudinal Analysis of Acute Liver Failure in Taiwan
por: Ho, Cheng-Maw, et al.
Publicado: (2014) -
Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chemoprevention of hepatocellular carcinoma: a nationwide high-risk cohort study
por: Ho, Cheng-Maw, et al.
Publicado: (2018) -
Prophylactic liver transplantation for high-risk recurrent hepatocellular carcinoma
por: Yang, Po-Chih, et al.
Publicado: (2016) -
Harnessing immunotherapy for liver recipients with hepatocellular carcinoma: a review from a transplant oncology perspective
por: Ho, Cheng-Maw, et al.
Publicado: (2019) -
Cross-Match as an Immuno-Oncological Risk Factor for Hepatocellular Carcinoma Recurrence and Inferior Survival After Living Donor Liver Transplantation: A Call for Further Investigation
por: Ho, Cheng-Maw, et al.
Publicado: (2020)